The primary objective was to determine the long-term safety of etanercept administered with or without other disease-modifying anti-rheumatic drugs (DMARDS) in pediatric subjects with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a control cohort of subjects with polyarticular course or systemic JRA receiving methotrexate (with or without other DMARDS)